AMT-253(Multitude)

N/A

Report date: 2024/07/09 20:00:06

Base Information

Drug NameAMT-253(Multitude)
Drug Alias NameAMT-253 ADCAMT-253
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionMelanoma cell adhesion molecule inhibitorsDNA topoisomerase I inhibitors
TargetsMelanoma cell adhesion moleculeDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesMultitude Therapeutics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesMultitude Therapeutics (Australia) Pty LtdMultitude Therapeutics Inc
Inactive CompaniesPuzhong Discovery Medical Technology (Shanghai) Co Ltd
Active IndicationsSolid tumoursMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A